[Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans]

An Pediatr (Barc). 2004 Sep;61(3):261-5. doi: 10.1016/s1695-4033(04)78806-2.
[Article in Spanish]


Meningococcal purpura fulminans (MPF) produces high mortality and morbidity, despite appropriate standard therapy. Administration of recombinant human activated protein C (rhAPC) has been successfully applied in adults with MPF and pediatric studies are under way. We report three pediatric patients with MPF treated with rhAPC as compassionate therapy. In two of these patients, positive clinical and laboratory effects were observed and both children achieved full recovery. The remaining patient died after 36 hours from refractory multiorgan failure. No rhAPC-related adverse effects were detected. The reported cases highlight the usefulness of rhAPC in children with MPF at least as a rescue compassionate treatment. Further clinical trials are needed to better delineate its efficacy and administration schedule in children.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Blood Coagulation Factors / analysis
  • Child, Preschool
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Male
  • Protein C / therapeutic use*
  • Recombinant Proteins / therapeutic use*
  • Treatment Outcome
  • Waterhouse-Friderichsen Syndrome / complications
  • Waterhouse-Friderichsen Syndrome / diagnosis
  • Waterhouse-Friderichsen Syndrome / drug therapy*


  • Blood Coagulation Factors
  • Fibrinolytic Agents
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated